19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Slides:



Advertisements
Similar presentations
Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Advertisements

May 29 - June 2, 2015 Borealis-1: Apatorsen + Gemcitabine/Cisplatin for Pts With Advanced Bladder Cancer CCO Independent Conference Highlights of the 2015.
Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida First-in-Human Trial: BCMA- Targeted CAR.
May 29 - June 2, 2015 Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Outcomes CCO Independent Conference Highlights of the 2015.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
CCO Independent Conference Highlights
CCO Independent Conference Highlights
CCO Independent Conference Highlights
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
CCO Independent Conference Coverage
CCO Independent Conference Highlights
CCO Independent Conference Coverage
CCO Independent Conference Highlights
CCO Independent Conference Highlights
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
CCO Independent Conference Coverage
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
Immunoscore Prognostic in Colon Cancer
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory FLT3-IDT AML CCO Independent Conference.
Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL
CCO Independent Conference Highlights
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
CCO Independent Conference Coverage
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
New Findings in Hematology: Independent Conference Coverage
New Findings in Hematology: Independent Conference Coverage
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
CCO Independent Conference Highlights
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma CCO Independent Conference Highlights of the 2015 ASCO Annual.
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases CCO Independent Conference Highlights*
CCO Independent Conference Coverage
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.
New Findings in Hematology: Independent Conference Coverage
Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*
Presentation transcript:

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. ALL, acute lymphoblastic leukemia; R/R, relapsed/refractory. This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

19-28z CAR T Cells in Relapsed/Refractory B-Cell ALL: Background Autologous T cells modified to express CAR that targets B-cell antigen CD19 When infused back into pt, will target CD19-positive tumor cells and induce cell death Phase I trial evaluated impact of preinfusion disease burden on long-term outcomes with CD19-targeted CAR T cells in adult pts with relapsed or refractory CD19-positive B-cell ALL[1] This analysis examined the impact of disease burden at time of CAR T-cell infusion on clinical outcome and toxicity[2] ALL, acute lymphoblastic leukemia. 1. ClinicalTrials.gov. NCT01044069. 2. Park JH, et al. ASCO 2016. Abstract 7003. Slide credit: clinicaloptions.com

19-28z CAR T Cells in R/R B-Cell ALL: Study Design Adult pts with relapsed/refractory CD19-positive B-cell ALL (N = 51) Autologous T cells derived by leukapheresis Pt pretreatment Salvage chemotherapy during T-cell expansion Bone marrow blast count to determine disease burden Conditioning chemotherapy on Day -2 Cyclophosphamide (n = 42) Fludarabine + cyclophosphamide (n = 9) ALL, acute lymphoblastic leukemia; R/R, relapsed/refractory. Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: Dosing and Assessment 19-28z CAR T-cell infusion; dosing based on disease burden 3 x 109 CAR T cells/kg in pts with minimal disease (< 5% blasts in BM); n = 20 (39%) Dose reduced to 1 x 109 CAR T cells/kg in pts with morphologic disease (≥ 5% blasts in BM or extramedullary disease); n = 31 (61%) Disease assessment: Days 28-35 Median follow-up: 8.5 mos ≥ 6 mos: 58% ≥ 1 yr: 34% ALL, acute lymphoblastic leukemia; BM, bone marrow; R/R, relapsed/refractory. Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: Patient Characteristics Morphologic Disease (n = 31) Minimal Disease (n = 20) Median age at infusion, yrs (range) 18-29, % 30-59, % ≥ 60, % 40 (24-73) 26 58 16 53 (22-74) 20 50 30 Median prior lines of therapy, n (range) 2, % 3, % ≥ 4, % 3 (2-7) 48 2 (2-4) 60 25 15 Prior blinatumomab, % 36 5 Prior allogeneic HSCT, % 42 Philadelphia chromosome positive, % 23 40 ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; R/R, relapsed/refractory. Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: Clinical Response Morphologic Disease (n = 30) Minimal Disease (n = 20) CR, % 77 90 MRD-negative CR, % 90 (n = 21) 78 (n = 18) Mean time to CR, days (SD) 20 (9) 25 (9) CR seen across analyzed subgroups, including disease burden, prior blinatumomab, prior HSCT, number of prior therapies, Philadelphia chromosome status, and age 39% of pts achieving CR proceeded to allogeneic HSCT (equal incidence in morphologic and minimal disease cohorts) 45% MRD-negative CR pts relapsed; 27% of these were CD19 positive 27% MRD-negative CR pts disease free for > 1 yr ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; R/R, relapsed/refractory; SD, standard deviation. Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: OS Response Morphologic Disease (n = 31) Minimal Disease (n = 20) Median OS, mos 9.0 NR Median OS in MRD-negative CR, mos 17.0 Median OS follow-up: 13.0 mos After CAR T cells, MRD negativity had prognostic implications Post–CAR T-cell HSCT does not appear to affect survival ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; NR, not reached. Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: Safety AE, % Morphologic Disease (n = 31) Minimal Disease (n = 20) Severe CRS 42 5 Grade 3/4 NT 35 20 Severe CRS + grade 3/4 NT 23 Severe CRS or grade 3/4 NT 55 Grade 5 toxicity 10* *n = 3: 2 pts with sepsis/multiorgan failure, 1 pt with seizure but unknown cause of death (all received higher CAR T-cell dose prior to dose modification). AE, adverse event; ALL, acute lymphoblastic leukemia; CRS, cytokine release syndrome; NT, neurologic toxicities; RFS, relapse-free survival; R/R, relapsed/refractory. Some AEs managed with tocilizumab and/or steroids; no effect on RFS or OS Slide credit: clinicaloptions.com Park JH, et al. ASCO 2016. Abstract 7003.

19-28z CAR T Cells in R/R B-Cell ALL: Conclusions CR and MRD-negative CR rates > 75% regardless of pretherapy disease burden[1] Durable responses and survival benefits in subset of patients without subsequent allogeneic HSCT (regardless of disease burden) Benefit of allogeneic HSCT after 19-28z CAR T cells unclear Lower incidence of severe CRS and neurologic toxicities in pts with minimal disease burden prior to pre–T-cell infusion Single-arm phase II trial of 19-28z CAR T cells in R/R B-cell ALL ongoing (ROCKET)[2] ALL, acute lymphoblastic leukemia; CR, complete remission; CRS, cytokine release syndrome; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; R/R, relapsed/refractory. Park JH, et al. ASCO 2016. Abstract 7003. ClinicalTrials.gov. NCT02535364. Slide credit: clinicaloptions.com

Go Online for More CCO Coverage of ASCO 2016! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in: Breast, Genitourinary, and Lung cancers Hematologic malignancies Immunotherapy clinicaloptions.com/oncology